Table 5.
Investigational agents
| Compound name | Medication class | Company |
|---|---|---|
| Phase 3 | ||
| Darunavir/cobicistat/emtricitabine/tenofovir alafenamidea | STR (PI + NRTIs) | Gilead Sciences |
| Dolutegravir/rilpivirinea | STR (INSTI + NNRTI) | ViiV/Janssen |
| Doravirine (MK-1439)a | NNRTI | Merck |
| Fostemsavir (BMS-663068)a | AI | ViiV |
| GS-9883/emtricitabine/tenofovir alafenamidea | STR (INSTI + NRTIs) | Gilead Sciences |
| Ibalizumab (TMB-355)a,b | EI | TaiMed Biologics |
| Raltegravir once dailya | INSTI | Merck |
| Phase 2b | ||
| BMS-955176a | MI | ViiV |
| Cabotegravir (LA)/Rilpivirine (LA)a (IM) | INSTI + NNRTIs | ViiV/Janssen |
| Cabotegravira (PO) | INSTI | ViiV |
| Cenicriviroca | CCR5 and CCR2 inhibitor | Takeda/Tobira Therapeutics |
| PRO-140a | EI | CytoDyn |
| Phase 1 | ||
| GS-9620c | TL7 agonist | Gilead Sciences |
AI attachment inhibitor, CCR C-C chemokine receptor, EI entry inhibitor, IM intramuscular, INSTI integrase strand transfer inhibitor, LA long-acting, MI maturation inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, NRTI nucleoside reverse transcriptase inhibitor, PO oral, PI protease inhibitor, STR single tablet regimen, TL7 Toll-like receptor
aFor treatment of HIV
bExpanded access available in the US
cBeing evaluated for HIV eradication